A private equity investor based in Greenwich, Connecticut, Great Point Partners has invested into more than 100 businesses in the public and private healthcare sector since 2003. Through December 2016 and January 2017, the private equity portfolio company Clinical Supplies Management (CSM) completed the acquisition of two companies that will expand its range of services in Europe.Theorem Clinical Supply (TCS) was the first of these acquisitions. A Frankfurt-based company that offers clinical trial drug labeling, storage, packaging, and distribution, TCS’ services extend throughout Western Europe. The acquisition, which it completed in December 2016, enables CSM to provide significantly improved services to its global clients.The TCS acquisition was complemented by the acquisition of Brussel’s B&C Group in January 2017. B&C provides a range of clinical trial supplies, in addition to biomedical sample services, via its custom system architecture, which CSM aims to leverage to serve the needs of its pharmaceutical clients in both Europe and the United States.
Maintaining an investment portfolio with portfolio companies primarily domiciled in the United States, Greenwich, Connecticut investment firm Great Point Partners (GPP) focuses primarily on health care companies. Among the firms Great Point Partners has invested in is Equian, which it sold in December 2015 to New Mountain Capital, LLC.A leading payment integrity solutions provider that offers services to medical claims payers, Equian became a Great Point Partner's portfolio company in 2007. In the eight years that Great Point Partner's and Equian worked together, Equian achieved and exceeded the market positioning and corporate growth goals that its co-founders John Ansay and Russ Sherlock set for the firm.In speaking about the sale that was achieved in December 2015 to New Mountain Capital, Great Point Partners’s principal Noah F. Rhodes III noted during GPP's investment period Equian had 11 add-on acquisitions and a strong annual earnings growth rate.
Headquartered in Connecticut, Great Point Partners is an investment management firm that specializes in the healthcare industry. Great Point Partners (GPP) was founded in 2003 and has invested in more than 100 healthcare businesses. The firm operates two separate divisions – one that focuses on private companies and one on public companies. Hedge funds are a limited partnership of investors that make investments. One type of hedge fund is the equity long/short hedge fund. Long/short hedge funds invest in the stock market buy buying and selling stocks.
Great Point Partners is a Greenwich, Connecticut-based investment firm that targets both the public and private health care sectors. For over a decade, Great Point Partners has invested in firms that are advancing the quality and accessibility of innovative health care products. A recent growth recapitalization facilitated by GPP has allowed Clinical Supplies Management (CSM), a provider of clinical trial services and solutions, to expand its offerings across the Atlantic Ocean. In December 2016, the company announced the acquisition of Theorem Clinical Research-Clinical Supplies (TCS), a German clinical services firm. Headquartered in Frankfurt, the former Chiltern International subsidiary provides services for the full clinical life cycle, including packaging, reconciliation, and distribution. Its inclusion within CSM’s growing portfolio will greatly enhance the firm’s ability to serve clients throughout western Europe. The new partnership between CSM and the Theorem team not only will allow CSM to increase its European presence, but also provides TCS with a gateway to North American clinical clients and resources. Following the acquisition, TCS executive director Rüdiger Weber will draw on his expertise in the sector to head the bourgeoning European operations of CSM.
Located in Greenwich, Connecticut, Great Point Partners was founded with the goal of investing in growing businesses in the health care field. In September 2015, Great Point Partners portfolio company Biotronic NeuroNetwork completed the acquisition of Neurowave Monitoring, marking its seventh tuck-in acquisition under the supervision of GPP.This acquisition took Biotronic’s mission of providing the highest quality intraoperative neural monitoring services a step forward. It aims for constant improvement with a team of experienced professionals, along with the support of a quality-assurance program. The overall vision is to offer a range of service that establishes Biotronic NeuroNetwork as a lead provider in the sector. It does this by supporting a patient-centric focus and investing in clinical trials, research, and continued education.The acquisition of Neurowave Monitoring has allowed Biotronic to continue its growth throughout Southern California while also granting it access to a team of technologists that can help the company further its vision.
Connecticut-based Great Point Partners is a healthcare investment firm that was founded in 2003. Great Point Partners invests in public and private sector healthcare organizations.Recently, the firm announced an acquisition completed by one of its portfolio companies, Aris Radiology. Aris acquired US Teleradiology in October of 2016, enhancing its status as one of the leading radiology providers in the United States. An acquisition is a common business tactic implemented by corporations as part of a broader growth strategy.Acquisitions refer to one corporation assuming control of another through cash transactions, the purchase of shares, or both. Acquisitions – also referred to as takeovers – are considered to be either friendly or hostile. A friendly acquisition occurs when the firm being acquired has agreed to the takeover and is involved in the process, while a hostile takeover does not include this mutual agreement. In a hostile acquisition, the acquiring firm forces the takeover to move forward by aggressively purchasing a majority share in the business.
Great Point Partners, based in Greenwich, Connecticut, manages capital in private and public equity funds. Great Point Partners recently provided growth recapitalization capital to Alliance Biomedical Research, a leader in clinical trial research that focuses on Phase II to IV clinical trials.Clinical trials occur in four phases. In Phase I, researchers test the treatment, medication, or device utilizing a small group of volunteers. This the first attempt to test with humans. The researchers evaluate the treatment in terms of safety, dosage (for medications), and repeated side effects.In Phase II, the treatment is monitored within a larger group of people, still being observed for contraindications and side effects.In Phase III, the treatment is tested within large groups to confirm that it is effective, to monitor side effects, and to compare it to other treatments currently available. The treatment is still being evaluated during this phase for safety issues.In Phase IV, the treatment is placed on the market. During this phase of the study, researchers evaluate the treatment among diverse groups of people, and collect information regarding the long-term side effects of the drug or treatment.
